SkinHealth Systems (SKIN) EBITDA (2020 - 2026)

SkinHealth Systems (SKIN) has reported EBITDA for 7 consecutive years, with $3.6 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, EBITDA rose 232.3% year-over-year to $3.6 million in Q2 2026; TTM through Jun 2026 was -$4.3 million, a 90.07% increase from a year earlier, with the FY2025 full-year figure at -$20.8 million, up 69.31% from the prior year.
• EBITDA was $3.6 million for Q2 2026 at SkinHealth Systems, up from -$1.8 million in the prior quarter.
• Over five years, EBITDA peaked at $3.6 million in Q2 2026 and troughed at -$82.1 million in Q3 2023.
• A 5-year average of -$13.5 million and a median of -$9.6 million in 2024 frame the typical range for EBITDA.
• Across the five-year window, EBITDA sank 1786.08% in 2023 and surged 232.3% in 2026, its largest moves.
• Over 5 years, EBITDA stood at -$2.4 million in 2022, then slumped by 650.0% to -$18.4 million in 2023, then jumped by 61.02% to -$7.2 million in 2024, then soared by 102.26% to $162000.0 in 2025, then soared by 2104.94% to $3.6 million in 2026.
• The last three EBITDA figures came in at $3.6 million (Q2 2026), -$1.8 million (Q1 2026), and $162000.0 (Q4 2025), per Business Quant data.